dc.contributor | Aristizabal, Fabio | |
dc.contributor | García Robayo, Dabeiba Adriana | |
dc.contributor | Farmacogenética del Cáncer | |
dc.creator | Castillo Castillo, Edith Yuliana | |
dc.date.accessioned | 2022-08-16T18:55:46Z | |
dc.date.available | 2022-08-16T18:55:46Z | |
dc.date.created | 2022-08-16T18:55:46Z | |
dc.date.issued | 2021 | |
dc.identifier | https://repositorio.unal.edu.co/handle/unal/81919 | |
dc.identifier | Universidad Nacional de Colombia | |
dc.identifier | Repositorio Institucional Universidad Nacional de Colombia | |
dc.identifier | https://repositorio.unal.edu.co/ | |
dc.description.abstract | Introducción: Los bifosfonatos (BP´s) son medicamentos para la prevención y
tratamiento de enfermedades metabólicas óseas, inhiben la vía del mevalonato, que
genera pérdida de función de los osteoclastos, esta vía también es afectada por las
estatinas, medicamentos usados para la prevención y manejo de enfermedades
cardiovasculares, sin embargo, son escasos los estudios que evalúan in vitro procesos de
osteogénesis en células tratadas con cada uno de estos medicamentos de forma aislada
y combinada. Objetivo: evaluar el efecto de Zoledronato, atorvastatina y su combinación,
en células madre de pulpa dental (DPSC) y osteoblastos (OB) diferenciados a partir de
estas, en la expresión de los genes COL1A1, OSC, BMP2, RUNX2, OSX, OPG, RANKL.
Métodos: se realizaron cultivos celulares de DPSC y OB, tratadas con Zolendronato,
Atorvastatina y su combinación, para hallar la concentración efectiva 30, 50 y 70;
posteriormente se evaluó la expresión de genes relacionados con metabolismo óseo.
Resultados: Las curvas dosis respuesta para los tratamientos individuales ATV o ZOL
mostraron un comportamiento antagonista dependiente de dosis, combinaciones
ATV+ZOL en altas concentraciones inducen muerte celular y para DPSC las menores
concentraciones generan un efecto proliferativo. La expresión génica en DPSC fue con
tendencia a la osteogénesis a concentraciones bajas de los fármacos individuales y en
combinación, para el caso de los OB la respuesta fue inhibitoria principalmente en las
combinaciones. Conclusiones: La respuesta a ATV y ZOL son dependientes del tipo
celular y la dosis empleada, en las DPSC los dos fármacos tienen acción agonista, y en
los osteoblastos diferenciados levemente antagonista. (Texto tomado de la fuente) | |
dc.description.abstract | Introduction: Bisphosphonates are drugs for the prevention and treatment of bone
metabolic diseases, they inhibit the mevalonate pathway, which causes loss of osteoclast
function; this pathway is also affected by statins, drugs used for the prevention and
management of cardiovascular diseases, however, there are few studies that evaluate in
vitro processes of osteogenesis in cells treated with each of these drugs in isolation and in
combination. Purpose: To evaluate the effect of Zoledronate, atorvastatin and its
combination, on dental pulp stem cells (DPSC) and osteoblasts (OB) differentiated from
DPSC on the expression of the genes COL1A1, OSC, BMP2, RUNX2, OSX, OPG and
RANKL. Methods: Cell cultures of DPSC and OB were performed, treated with
Zolendronate, Atorvastatin and their combination, to find the effective concentration 30, 50
and 70; subsequently, the expression of genes related to bone metabolism was evaluated.
Results: The dose response curves for the individual ATV or ZOL treatments showed a
dose-dependent antagonistic behavior, and their combinations in high concentrations
induce cell death, and for DPSC the lower concentrations generate a proliferative effect.
The gene expression in DPSC was with a tendency to osteogenesis at low concentrations
of the individual drugs and in combination, in the case of the OB, the response was
inhibitory, especially in the combinations. Conclusion: The response to ATV and ZOL are
dependent on the cell type and the dose used, in DPSC the two drugs have an agonist
action, and in differentiated osteoblasts slightly antagonistic. | |
dc.language | spa | |
dc.publisher | Universidad Nacional de Colombia | |
dc.publisher | Bogotá - Ciencias - Maestría en Ciencias - Farmacología | |
dc.publisher | Departamento de Farmacia | |
dc.publisher | Facultad de Ciencias | |
dc.publisher | Universidad Nacional de Colombia - Sede Bogotá | |
dc.relation | RedCol | |
dc.relation | LaReferencia | |
dc.relation | Abdik, H., Avşar Abdik, E., Turan, D., Doğan, A., Demirci, S., & Şahin, F. (2018). The effects
of bisphosphonates on osteonecrosis of jaw bone: a stem cell perspective. Molecular
Biology Reports, 0(0), 0. https://doi.org/10.1007/s11033-018-4532-x | |
dc.relation | Aghaloo, T. L., Cheong, S., Bezouglaia, O., Kostenuik, P., Atti, E., Dry, S. M., Pirih, F. Q.,
& Tetradis, S. (2014). RANKL inhibitors induce osteonecrosis of the jaw in mice with
periapical disease. Journal of bone and mineral research : the official journal of the
American Society for Bone and Mineral Research, 29(4), 843–854.
https://doi.org/10.1002/jbmr.2097 | |
dc.relation | AlKhalil, M., Al-Hiari, Y., Kasabri, V., Arabiyat, S., Al-Zweiri, M., Mamdooh, N., & Telfah, A.
(2020). Selected pharmacotherapy agents as antiproliferative and anti-inflammatory
compounds. Drug Development Research, 81(4), 470–490.
https://doi.org/10.1002/ddr.21640 | |
dc.relation | Alsalih, A., Dam, A., Lindberg, P., & Truedsson, A. (2021). Medication-related
osteonecrosis of the jaws initiated by zoledronic acid and potential pathophysiology.
Dentistry Journal, 9(8), 1–13. https://doi.org/10.3390/dj9080085 | |
dc.relation | Black, D. M., & Rosen, C. J. (2016). Postmenopausal Osteoporosis. New England Journal
of Medicine, 374(3), 254–262. https://doi.org/10.1056/NEJMcp1513724 | |
dc.relation | Boyce, B. F., & Xing, L. (2007). The RANKL/RANK/OPG pathway. Current osteoporosis
reports, 5(3), 98–104. https://doi.org/10.1007/s11914-007-0024-y | |
dc.relation | Boyce, B. F., & Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis
research & therapy, 9 Suppl 1(Suppl 1), S1. https://doi.org/10.1186/ar2165 | |
dc.relation | Capulli, M., Paone, R., & Rucci, N. (2014). Osteoblast and osteocyte: Games without
frontiers. Archives of Biochemistry and Biophysics, 561(May), 3–12.
https://doi.org/10.1016/j.abb.2014.05.003 | |
dc.relation | Charles, J. F., & Aliprantis, A. O. (2014). Osteoclasts: More than “bone eaters.” Trends in
Molecular Medicine, 20(8), 449–459. https://doi.org/10.1016/j.molmed.2014.06.001 | |
dc.relation | Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013). The osteocyte: An endocrine cell . . .
and more. Endocrine Reviews, 34(5), 658–690. https://doi.org/10.1210/er.2012-1026 | |
dc.relation | Dolci, G. S., Ballarini, A., Gameiro, G. H., Onofre de Souza, D., de Melo, F., & Fossati, A.
C. M. (2018). Atorvastatin inhibits osteoclastogenesis and arrests tooth movement.
American Journal of Orthodontics and Dentofacial Orthopedics, 153(6), 872–882.
https://doi.org/10.1016/j.ajodo.2017.09.021 | |
dc.relation | Edwards, C. J., & Spector, T. D. (2002). Statins as modulators of bone formation. Arthritis
Research, 4(3), 151–153. https://doi.org/10.1186/ar399 | |
dc.relation | Endo, Y., Kumamoto, H., Nakamura, M., Sugawara, S., Takahashi, T., Sasaki, K., &
Takano-Yamamoto, T. (2017). Underlying Mechanisms and Therapeutic Strategies for
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Biological &
Pharmaceutical BulletinBiological and Pharmaceutical Bulletin, 40(6), 739–750.
https://doi.org/10.1248/bpb.b16-01020 | |
dc.relation | Fung, P. L., Nicoletti, P., Shen, Y., Porter, S., & Fedele, S. (2015). Pharmacogenetics of
Bisphosphonate-associated Osteonecrosis of the Jaw. Oral and Maxillofacial Surgery
Clinics of North America, 27(4), 537–546. https://doi.org/10.1016/j.coms.2015.06.005 | |
dc.relation | Gaviria-Mendoza, A., Machado-Duque, M. E., & Machado-Alba, J. E. (2019). Lipid-lowering
drug prescriptions in a group of Colombian patients. Patrones de prescripción de
hipolipemiantes en pacientes de Colombia. Biomedica : revista del Instituto Nacional
de Salud, 39(4), 759–768. https://doi.org/10.7705/biomedica.4801 | |
dc.relation | Hong, W., Wei, Z., Qiu, Z., Li, Z., Fu, C., Ye, Z., & Xu, X. (2020). Atorvastatin promotes
bone formation in aged apoE-/-mice through the Sirt1-Runx2 axis. Journal of
Orthopaedic Surgery and Research, 15(1), 1–9. https://doi.org/10.1186/s13018-020-
01841-0 | |
dc.relation | Horiuchi, N., & Maeda, T. (2006). Statins and bone metabolism. Oral Diseases, 12(2), 85–
101. https://doi.org/10.1111/j.1601-0825.2005.01172.x | |
dc.relation | Huang, X., Huang, S., Guo, F., Xu, F., Cheng, P., Ye, Y., … Chen, A. (2016). Dosedependent inhibitory effects of zoledronic acid on osteoblast viability and function in
vitro. Molecular Medicine Reports, 13(1), 613–622.
https://doi.org/10.3892/mmr.2015.4627 | |
dc.relation | Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019). RANKL/RANK/OPG system beyond bone remodeling: Involvement in breast cancerand clinical perspectives. Journal of Experimental and Clinical Cancer Research, 38(1), 1–18. https://doi.org/10.1186/s13046-018-1001-2 | |
dc.relation | Jadhav, S. B., & Jain, G. K. (2010). Statins and osteoporosis: new role for old drugs. Journal
of Pharmacy and Pharmacology, 58(1), 3–18. https://doi.org/10.1211/jpp.58.1.0002 | |
dc.relation | Jiang, N., Chen, M., Yang, G., Xiang, L., He, L., Hei, T. K., … Mao, J. J. (2016).
Hematopoietic Stem Cells in Neural-crest Derived Bone Marrow. Scientific Reports, 6,
1–11. https://doi.org/10.1038/srep36411 | |
dc.relation | Komori, T. (2018). Runx2, an inducer of osteoblast and chondrocyte differentiation.
Histochemistry and Cell Biology, 149(4), 313–323. https://doi.org/10.1007/s00418-
018-1640-6 | |
dc.relation | Komori, T. (2020). Functions of osteocalcin in bone, pancreas, testis, and muscle.
International Journal of Molecular Sciences, 21(20), 1–15.
https://doi.org/10.3390/ijms21207513 | |
dc.relation | Kook, S. H., Lee, D., Cho, E. S., Heo, J. S., Poudel, S. B., Ahn, Y. H., … Lee, J. C. (2016).
Activation of canonical Wnt/β-catenin signaling inhibits H2O2-induced decreases in
proliferation and differentiation of human periodontal ligament fibroblasts. Molecular
and Cellular Biochemistry, 411(1–2), 83–94. https://doi.org/10.1007/s11010-015-
2570-4 | |
dc.relation | Kuźnik, A., Październiok-Holewa, A., Jewula, P., & Kuźnik, N. (2020). Bisphosphonates—
much more than only drugs for bone diseases. European Journal of Pharmacology,
866(November). https://doi.org/10.1016/j.ejphar.2019.172773 | |
dc.relation | Landesberg, R., Woo, V., Cremers, S., Cozin, M., Marolt, D., Vunjak-novakovic, G., …
Surgery, M. (2015). HHS Public Access. 62–79. https://doi.org/10.1111/j.1749-
6632.2010.05835.x.Potential | |
dc.relation | Liu, Q., Li, M., Wang, S., Xiao, Z., Xiong, Y., & Wang, G. (2020). Recent Advances of
Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation.
Frontiers in Cell and Developmental Biology, 8(December).
https://doi.org/10.3389/fcell.2020.601224 | |
dc.relation | Manzano-Moreno, F. J., Ramos-Torrecillas, J., Melguizo-Rodríguez, L., Ruiz, C., IllescasMontes, R., & García-Martínez, O. (2018). Bisphosphonate Modulation of the Gene
Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw. International
Journal of Medical Sciences, 15(4), 359–367. https://doi.org/10.7150/ijms.22627 | |
dc.relation | Mansueto. P., Vitale. G., Seidita. A., Guarneri. F.P., Pepe I. et al. (2011). Mevalonate
pathway: Role of bisphosphonates and statins. Acta Medica Mediterranea, 27(2), 85–
95. | |
dc.relation | Medina Orjuela, A., Terront Lozano, A., Román González, A., Vélez Patiño, J. A., Linares
Restrepo, F., Rueda Beltz, C., … Vargas Grajales, F. I. (2018). II Consenso
Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Revista
Colombiana de Reumatología, 25(3), 184–210.
https://doi.org/10.1016/j.rcreu.2018.02.006 | |
dc.relation | Moradifard, S., Hoseinbeyki, M., Emam, M. M., Parchiniparchin, F., & Ebrahimi-Rad, M.
(2020). Association of the Sp1 binding site and -1997 promoter variations in COL1A1
with osteoporosis risk: The application of meta-analysis and bioinformatics
approaches offers a new perspective for future research. Mutation Research -
Reviews in Mutation Research, 786, 108339.
https://doi.org/10.1016/j.mrrev.2020.108339 | |
dc.relation | Morse, L. R., Coker, J., & Battaglino, R. A. (2018). STATINS AND BONE HEALTH : A MINI
REVIEW. 14(1), 31–35. | |
dc.relation | Motyl, K. J., Guntur, A. R., Carvalho, A. L., & Rosen, C. J. (2017). Energy Metabolism of
Bone. Toxicologic Pathology, 45(7), 887–893.
https://doi.org/10.1177/0192623317737065 | |
dc.relation | NH, Beth-tasdoganMayer, B., Hussein, H., & Zolk, O. (2017). Interventions for managing
medication-related osteonecrosis of the jaw ( Review ) SUMMARY OF FINDINGS
FOR THE MAIN COMPARISON. (10).
https://doi.org/10.1002/14651858.CD012432.pub2.www.cochranelibrary.com | |
dc.relation | Pourgonabadi, S., Ghorbani, A., Tayarani Najarn, Z., & Mousavi, S. H. (2018). In vitro
assessment of alendronate toxic and apoptotic effects on human dental pulp stem
cells. Iranian Journal of Basic Medical Sciences, 21(9), 905–910.
https://doi.org/10.22038/IJBMS.2018.22877.5816 | |
dc.relation | Prideaux, M., Findlay, D. M., & Atkins, G. J. (2016). Osteocytes: The master cells in bone
remodelling. Current Opinion in Pharmacology, 28, 24–30. https://doi.org/10.1016/j.coph.2016.02.003 | |
dc.relation | Rattazzi, M., Faggin, E., Buso, R., Di Virgilio, R., Puato, M., Plebani, M., … Pauletto, P.
(2016). Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL
Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.
Cardiovascular Therapeutics, 34(1), 13–20. https://doi.org/10.1111/1755-5922.12163 | |
dc.relation | Ruan, F., Zheng,Ruan, F., Zheng, Q., & Wang, J. (2012). Mechanisms of bone anabolism
regulated by statins. Bioscience Reports, 32(6), 511–519.
https://doi.org/10.1042/bsr20110118 Qiang, & Wang, J. (2012). Mechanisms of bone
anabolism regulated by statins. Bioscience Reports, 32(6), 511–519.
https://doi.org/10.1042/bsr20110118 | |
dc.relation | Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., &
O’Ryan, F. (2014). American association of oral and maxillofacial surgeons position
paper on medication-related osteonecrosis of the jaw - 2014 update. Journal of Oral
and Maxillofacial Surgery, 72(10), 1938–1956.
https://doi.org/10.1016/j.joms.2014.04.031 | |
dc.relation | Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Smith, G. D., …
Ebrahim, S. (2013). Statins for the primary prevention of cardiovascular disease
(Review). Cochrane Database of Systematic Reviews, (1), 1–97.
https://doi.org/10.1002/14651858.CD004816.pub5.www.cochranelibrary.com | |
dc.relation | Tenenbaum, H. C., Shelemay, A., Girard, B., Zohar, R., & Fritz, P. C. (2002).
Bisphosphonates and periodontics: potential applications for regulation of bone mass
in the periodontium and other therapeutic/diagnostic uses. Journal of
periodontology, 73(7), 813–822. https://doi.org/10.1902/jop.2002.73.7.813 | |
dc.relation | Ting, M., Whitaker, E. J., & Albandar, J. M. (2016). Systematic review of the in vitro effects
of statins on oral and perioral microorganisms. European Journal of Oral Sciences,
124(1), 4–10. https://doi.org/10.1111/eos.12239 | |
dc.relation | Unal, M., Creecy, A., & Nyman, J. S. (2018). The Role of Matrix Composition in the
Mechanical Behavior of Bone. Current Osteoporosis Reports, 16(3), 205–215.
https://doi.org/10.1007/s11914-018-0433-0 | |
dc.relation | Valencia, A., Páez, A., Sampedro, M., Ávila, C., Cardona, J., & Mesa, C. (2012).
Publicación Anticipada En Linea. Biomédica, 32(4), 1–27. | |
dc.relation | Von Moos, R., Costa, L., Gonzalez-Suarez, E., Terpos, E., Niepel, D., & Body, J. J. (2019).
Management of bone health in solid tumours: From bisphosphonates to a monoclonal
antibody. Cancer Treatment Reviews, 76(December 2018), 57–67.
https://doi.org/10.1016/j.ctrv.2019.05.003 | |
dc.relation | Wang, L., Fang, D., Xu, J., & Luo, R. (2020). Various pathways of zoledronic acid against
osteoclasts and bone cancer metastasis: a brief review. BMC Cancer, 20(1), 1–10.
https://doi.org/10.1186/s12885-020-07568-9 | |
dc.relation | Zhao, B. J., & Liu, Y. H. (2014). Simvastatin induces the osteogenic differentiation of human
periodontal ligament stem cells. Fundamental and Clinical Pharmacology, 28(5), 583–
592. https://doi.org/10.1111/fcp.12050 | |
dc.rights | Atribución-NoComercial 4.0 Internacional | |
dc.rights | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Evaluación del efecto de Zoledronato, Atorvastatina y su combinación, en células madre de pulpa dental (DPSC) y osteoblastos diferenciados a partir de DPSC, en la expresión de genes relacionados con la diferenciación celular, maduración e interacciones osteoblasto/osteoclasto | |
dc.type | Trabajo de grado - Maestría | |